Peptide Amide Composition for Kappa Opioid Receptor Treatment
Summary
USPTO granted Patent US12599647B2 to Xizang Haisco Pharmaceutical Co., Ltd. for a peptide amide composition containing a compound of formula (I) and pH regulators (pH 3-5.5). The composition is designed for treating or preventing diseases or conditions associated with kappa opioid receptors. The patent includes 19 claims and covers the compound composition, preparation methods, and medical applications.
What changed
USPTO granted Patent US12599647B2 to Xizang Haisco Pharmaceutical Co., Ltd. covering a peptide amide composition with pH regulators for stable clinical use in treating kappa opioid receptor-associated conditions. The patent includes claims on the compound formulation, preparation method, and medical use applications.
Pharmaceutical companies developing kappa opioid receptor-targeted therapeutics should conduct Freedom to Operate analyses to assess potential infringement risks. Competitors in the peptide pharmaceutical space may need to design around these claims or seek licensing arrangements with the patent holder.
What to do next
- Monitor for potential licensing opportunities
- Conduct Freedom to Operate analysis if developing similar kappa opioid therapeutics
- Review patent claims for any infringement risks
Archived snapshot
Apr 15, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Peptide amide composition and preparation method therefor
Grant US12599647B2 Kind: B2 Apr 14, 2026
Assignee
Xizang Haisco Pharmaceutical Co., Ltd.
Inventors
Yi Mo, Honghu Li, Li Zhang, Xiangling Ma, Can Zhao
Abstract
Disclosed are a peptide amide compound composition, a preparation method therefor and medical use thereof. Specifically, the composition contains a compound of formula (I) and pH regulators, and the pH of the solution thereof is 3-5.5. The composition is stable and requires few excipients, and is stable in clinical use. The composition is used for treating or preventing a disease or condition associated with kappa opioid receptors
CPC Classifications
A61K 38/07 A61K 47/02 A61K 47/12 A61K 9/0019 A61K 9/19 A61K 47/183 A61K 38/00 C07K 5/10 C07K 5/1016
Filing Date
2020-08-24
Application No.
17637189
Claims
19
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.